All In Biotech

Investigational drug · Phase 2

NT-101

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Wet Age Related Macular Degeneration, Wet AMD.

Phase 2

Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

2

1 still active

All registered trials

3

Any phase or sponsor naming "NT-101"

First trial start

2025

Mar 11, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "NT-101", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Wet Age Related Macular Degeneration
  • Wet AMD

Approved drugs for the same conditions: Wet macular degeneration · Ophthalmology

Largest trials

Live from ClinicalTrials.gov: studies naming "NT-101" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 10 on PubMed

Also in development for Wet Age Related Macular Degeneration

  • EYP-1901Phase 34 trials

    EyePoint Pharmaceuticals, Inc. · Diabetic Macular Edema, DME, Diabetic Macular Edema (DME)

  • OLN324Phase 34 trials

    Ollin Biosciences, Inc. · Diabetic Macular Edema (DME), Wet Age Related Macular Degeneration, Wet Age-related Macular Degeneration

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.